Bruker: Philip Ma

Bruker has appointed Philip Ma to its board of directors. Ma is the CEO, founder, and a director of PrognomiQ, a multiomics diagnostics firm developing tests for the early detection of cancer and guiding cancer treatments. Ma was previously chief business officer, president, and co-founder of proteomics company Seer, which is an investor in PrognomiQ. Before that he was vice president for digital health technologies and data sciences at Biogen.